{"disease":{"id":"familial-hypercholesterolemia","name":"Familial hypercholesterolemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"evolocumab","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"atorvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"atorvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"inclisiran","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqvio","generic_name":"INCLISIRAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":59,"revenue":"863","mechanism":"Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors."},{"drug_id":"alirocumab","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"lomitapide","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Juxtapid","generic_name":"LOMITAPIDE","company_name":"Chiesi","drug_phase":"marketed","molecular_target":"Microsomal triglyceride transfer protein large subunit","drug_class":"Microsomal Triglyceride Transfer Protein Inhibitor","quality_score":60,"revenue":"126","mechanism":"Juxtapid works by blocking the protein that helps transport cholesterol into the bloodstream."},{"drug_id":"mipomersen","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kynamro","generic_name":"MIPOMERSEN","company_name":"Kastle Theraps Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Antisense Oligonucleotide","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"fluvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"ezetimibe","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"ezetimibe","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"livalo","indication_name":"Familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livalo","company_name":"Kowa Research Institute, Inc.","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Retinoic acid receptor RXR-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"simvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"praluent","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"evinacumab-dgnb","indication_name":"Homozygous familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EVKEEZA","generic_name":"EVINACUMAB-DGNB","company_name":"REGENERON PHARMACEUTICALS","drug_phase":"marketed","molecular_target":"Angiopoietin-related protein 3","drug_class":"Angiopoietin-like 3 Inhibitor [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"niacin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"fenofibrate","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"rosuvastatin","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"bempedoic-acid","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nexletol","generic_name":"BEMPEDOIC ACID","company_name":"Esperion Theraps Inc","drug_phase":"marketed","molecular_target":"ATP-citrate lyase (ACL), Niemann-Pick C1-Like 1 (NPC1L1)","drug_class":"Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":"NEXLIZET reduces LDL-C by inhibiting cholesterol synthesis in the liver and absorption in the intestine."},{"drug_id":"lipitor","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"lipitor","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"evinacumab","indication_name":"Homozygous familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evkeeza","generic_name":"EVINACUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Angiopoietin-related protein 3","drug_class":"Angiopoietin-like 3 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Evkeeza works by blocking the action of Angiopoietin-related protein 3, a protein that helps regulate cholesterol levels in the blood."},{"drug_id":"choline-fenofibrate","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pitavastatin","indication_name":"Familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livalo","generic_name":"PITAVASTATIN","company_name":"Kowa Co","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"caduet","indication_name":"Heterozygous Familial Hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"lovastatin","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"caduet","indication_name":"Homozygous Familial Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"nicotinic-acid","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"ezetrol","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"ezetrol","indication_name":"Familial hypercholesterolemia - homozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"lerodalcibep","indication_name":"heterozygous familial hypercholesterolemia (HeFH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lerochol","generic_name":"LERODALCIBEP","company_name":"Lib Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":null,"mechanism":"Lerodalcibep works by modulating a specific biological pathway to lower cholesterol levels."},{"drug_id":"niaspan","indication_name":"Familial hypercholesterolemia - heterozygous","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":34,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07023445","title":"Patterns of Inclisiran Use in the Real World: An Analysis of US Databases","phase":"","overall_status":"COMPLETED","enrollment_count":37688,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04507984","title":"Universal Familial Hypercholesterolemia Screening in Children","phase":"","overall_status":"COMPLETED","enrollment_count":17000,"lead_sponsor_name":"University of Ljubljana, Faculty of Medicine","has_results":false},{"nct_id":"NCT04529967","title":"Child-Parent Familial Hypercholesterolemia Screening","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT06362473","title":"Lipid Transport Disorder Italian Genetic Record (LIPIGEN)","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","has_results":false},{"nct_id":"NCT02808403","title":"Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03814187","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05952856","title":"A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2912,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05142722","title":"Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2530,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT04798430","title":"Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"LIB Therapeutics LLC","has_results":false},{"nct_id":"NCT05614219","title":"Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT05271305","title":"Pilot Study for a National Screening for Familial Hypercholesterolemia","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Centre Hospitalier du Luxembourg","has_results":false},{"nct_id":"NCT03110432","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1695,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT03694197","title":"Long Term Safety Study of PRALUENT","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":1389,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT03398954","title":"a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia","phase":"","overall_status":"UNKNOWN","enrollment_count":1128,"lead_sponsor_name":"China Cardiovascular Association","has_results":false},{"nct_id":"NCT04815005","title":"HoFH, the International Clinical Collaborators Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03597958","title":"Genetic Causes of Hypercholesterolaemia in the Emirati Population","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Imperial College London Diabetes Centre","has_results":false},{"nct_id":"NCT03110250","title":"Familial Hypercholesterolemia in Turkey (A-HIT2)","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT03140605","title":"Greek Registry - Familial Hypercholesterolaemia","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Hellenic College of Treatment of Atherosclerosis","has_results":false},{"nct_id":"NCT07421284","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":900,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT03310671","title":"Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Instituto Aragones de Ciencias de la Salud","has_results":false},{"nct_id":"NCT05750667","title":"Penn Family Screening for Familial Hypercholesterolemia","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT07421297","title":"A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":760,"lead_sponsor_name":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","has_results":false},{"nct_id":"NCT05746247","title":"Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":750,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04885218","title":"Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":692,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06546137","title":"National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospital do Coracao","has_results":false},{"nct_id":"NCT06960902","title":"Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03234127","title":"Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03397121","title":"Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":482,"lead_sponsor_name":"The Medicines Company","has_results":true},{"nct_id":"NCT04797104","title":"Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":478,"lead_sponsor_name":"LIB Therapeutics LLC","has_results":false},{"nct_id":"NCT03640234","title":"Return of Actionable Variants Empirical Study","phase":"","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06005597","title":"Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":407,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT03934320","title":"Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"University of Nottingham","has_results":false},{"nct_id":"NCT04370899","title":"Early Detection of Familial Hypercholesterolemia in Children","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT03060577","title":"An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05261126","title":"A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":381,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04419090","title":"Cascade Genetic Testing of Familial Hypercholesterolemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":379,"lead_sponsor_name":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","has_results":false},{"nct_id":"NCT03253432","title":"IN-TANDEM Familial Hypercholesterolemia Pilot Study","phase":"","overall_status":"COMPLETED","enrollment_count":378,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT01968980","title":"A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":370,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05425745","title":"Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT04958629","title":"A Prospective Cohort Study on Familial Hypercholesterolemia in Health Examination Population","phase":"","overall_status":"UNKNOWN","enrollment_count":318,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT04666298","title":"Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05952869","title":"A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":303,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02135705","title":"LOWER: Lomitapide Observational Worldwide Evaluation Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Amryt Pharma","has_results":false},{"nct_id":"NCT07427472","title":"\"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)\"","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06571630","title":"PMMHRI - Familial Hypercholesterolemia Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Polish Mother Memorial Hospital Research Institute","has_results":false},{"nct_id":"NCT01624142","title":"Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03501875","title":"Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous","phase":"NA","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06439654","title":"Atlantic Lipid Lowering Treatment Optimization Program","phase":"NA","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Atlantic Health System","has_results":false},{"nct_id":"NCT06634160","title":"Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06958315","title":"Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}